{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:45:43Z","timestamp":1777632343804,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To prevent the spread of the novel coronavirus disease 2019 (COVID-19) infection, various vaccines have been developed and used in a large number of people worldwide. One of the most commonly used vaccines is the mRNA vaccine developed by Moderna. Although several studies have shown this vaccine to be safe, the full extent of its side effects has not yet been known. Miller-Fisher syndrome (MFS) is a rare condition that manifests ophthalmoplegia, ataxia, and loss of tendon reflexes. It is a subtype of Guillain\u2013Barr\u00e9 syndrome and an immune-mediated disease related to serum IgG anti-GQ1b antibodies. Several vaccines including those for COVID-19 have been reported to induce MFS. However, there have been no reports of MFS following Moderna COVID-19 vaccine administration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 70-year-old man was referred to our hospital due to diplopia that manifested 1 week after receiving the second Moderna vaccine dose. The patient presented with restricted abduction of both eyes, mild ataxia, and loss of tendon reflexes. He was diagnosed with MFS based on his neurological findings and detection of serum anti-GQ1b antibodies. The patient was administered intravenous immunoglobulin, and his symptoms gradually improved. Five days after admission, the patient showed peripheral facial paralysis on the right side. This symptom was suggested to be a delayed onset of peripheral facial nerve palsy following MFS that gradually improved by administration of steroids and antiviral drugs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>There have been no previous reports of MFS after Moderna COVID-19 vaccination. This case may provide new information about the possible neurological side effects of COVID-19 vaccines.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-022-02838-4","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T13:06:14Z","timestamp":1661173574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["A case of Miller Fisher syndrome with delayed onset peripheral facial nerve palsy after COVID-19 vaccination: a case report"],"prefix":"10.1186","volume":"22","author":[{"given":"Kentaro","family":"Nanatsue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2452-0268","authenticated-orcid":false,"given":"Makoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakiko","family":"Itaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"key":"2838_CR1","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1001\/jama.2021.5374","volume":"325","author":"J Chapin-Bardales","year":"2021","unstructured":"Chapin-Bardales J, Gee J, Myers T. Reactogenicity following receipt of mrna-based COVID-19 vaccines. JAMA. 2021;325:2201\u20132. https:\/\/doi.org\/10.1001\/jama.2021.5374.","journal-title":"JAMA"},{"key":"2838_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1056\/NEJM195607122550201","volume":"255","author":"M Fisher","year":"1956","unstructured":"Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and Areflexia). N Engl J Med. 1956;255:57\u201365. https:\/\/doi.org\/10.1056\/NEJM195607122550201.","journal-title":"N Engl J Med"},{"key":"2838_CR3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/ana.410310619","volume":"31","author":"A Chiba","year":"1992","unstructured":"Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of miller Fisher syndrome. Ann Neurol. 1992;31:677\u20139. https:\/\/doi.org\/10.1002\/ana.410310619.","journal-title":"Ann Neurol"},{"key":"2838_CR4","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00415-019-09308-x","volume":"266","author":"M Koga","year":"2019","unstructured":"Koga M, Kishi M, Fukusako T, Ikuta N, Kato M, Kanda T. Antecedent infections in Fisher syndrome: sources of variation in clinical characteristics. J Neurol. 2019;266:1655\u201362. https:\/\/doi.org\/10.1007\/s00415-019-09308-x.","journal-title":"J Neurol"},{"key":"2838_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1586\/ern.11.182","volume":"12","author":"M Mori","year":"2012","unstructured":"Mori M, Kuwabara S, Yuki N. Fisher syndrome: clinical features, immunopathogenesis and management. Expert Rev Neurother. 2012;12:39\u201351. https:\/\/doi.org\/10.1586\/ern.11.182.","journal-title":"Expert Rev Neurother"},{"key":"2838_CR6","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1212\/wnl.56.8.1104","volume":"56","author":"M Mori","year":"2001","unstructured":"Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinical features and prognosis of miller Fisher syndrome. Neurology. 2001;56:1104\u20136. https:\/\/doi.org\/10.1212\/wnl.56.8.1104.","journal-title":"Neurology."},{"key":"2838_CR7","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/mus.24475","volume":"51","author":"M Tatsumoto","year":"2015","unstructured":"Tatsumoto M, Misawa S, Kokubun N, Sekiguchi Y, Hirata K, Kuwabara S, et al. Delayed facial weakness in Guillain-Barre and miller Fisher syndromes. Muscle Nerve. 2015;51:811\u20134. https:\/\/doi.org\/10.1002\/mus.24475.","journal-title":"Muscle Nerve"},{"key":"2838_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clineuro.2015.04.025","volume":"135","author":"JK Kim","year":"2015","unstructured":"Kim JK, Kim BJ, Shin HY, Shin KJ, Nam TS, Seok JI, et al. Does delayed facial involvement implicate a pattern of \u201cdescending reversible paralysis\u201d in Fisher syndrome? Clin Neurol Neurosurg. 2015;135:1\u20135. https:\/\/doi.org\/10.1016\/j.clineuro.2015.04.025.","journal-title":"Clin Neurol Neurosurg"},{"key":"2838_CR9","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1212\/wnl.57.4.686","volume":"57","author":"M Koga","year":"2001","unstructured":"Koga M, Yuki N, Tai T, Hirata K. Miller Fisher syndrome and Haemophilus influenzae infection. Neurology. 2001;57:686\u201391. https:\/\/doi.org\/10.1212\/wnl.57.4.686.","journal-title":"Neurology"},{"key":"2838_CR10","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/ana.410360517","volume":"36","author":"N Yuki","year":"1994","unstructured":"Yuki N, Taki T, Takahashi M, Saito K, Yoshino H, Tai T, et al. Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of campylobacter jejuni isolated from patients with Fisher's syndrome. Ann Neurol. 1994;36:791\u20133. https:\/\/doi.org\/10.1002\/ana.410360517.","journal-title":"Ann Neurol"},{"key":"2838_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/19418744211016709","volume":"12","author":"S Biswas","year":"2022","unstructured":"Biswas S, Ghosh R, Mandal A, Pandit A, Roy D, Sengupta S, et al. COVID-19 induced miller Fisher syndrome presenting with autonomic dysfunction: a unique case report and review of literature. Neurohospitalist. 2022;12:111\u20136. https:\/\/doi.org\/10.1177\/19418744211016709.","journal-title":"Neurohospitalist"},{"issue":"15\u201320","key":"2838_CR12","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1468-1331.2011.03445.x","volume":"19","author":"Z Ar\u00e1nyi","year":"2012","unstructured":"Ar\u00e1nyi Z, Kov\u00e1cs T, Sipos I, Bereczki D. Miller Fisher syndrome: brief overview and update with a focus on electrophysiological findings. Eur J Neurol. 2012;19(15\u201320):e1\u20133. https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03445.x.","journal-title":"Eur J Neurol"},{"key":"2838_CR13","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/archneurol.2011.236","volume":"68","author":"A Shoamanesh","year":"2011","unstructured":"Shoamanesh A, Chapman K, Traboulsee A. Postvaccination miller Fisher syndrome. Arch Neurol. 2011;68:1327\u20139. https:\/\/doi.org\/10.1001\/archneurol.2011.236.","journal-title":"Arch Neurol"},{"key":"2838_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jamda.2008.01.013","volume":"9","author":"A Thaler","year":"2008","unstructured":"Thaler A. Miller Fisher syndrome in a 66-year-old female after flu and pneumovax vaccinations. J Am Med Dir Assoc. 2008;9:283\u20134. https:\/\/doi.org\/10.1016\/j.jamda.2008.01.013.","journal-title":"J Am Med Dir Assoc"},{"key":"2838_CR15","doi-asserted-by":"publisher","unstructured":"Yamakawa M, Nakahara K, Nakanishi T, Nomura T, Ueda M. Miller Fisher syndrome following vaccination against SARS-Cov-2. Intern Med. 61:1067\u20139. https:\/\/doi.org\/10.2169\/internalmedicine.8851-21.","DOI":"10.2169\/internalmedicine.8851-21"},{"key":"2838_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1186\/s12883-021-02489-x","volume":"21","author":"Y Nishiguchi","year":"2021","unstructured":"Nishiguchi Y, Matsuyama H, Maeda K, Shindo A, Tomimoto H. Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination. BMC Neurol. 2021;21:452. https:\/\/doi.org\/10.1186\/s12883-021-02489-x.","journal-title":"BMC Neurol"},{"key":"2838_CR17","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s10072-021-05776-0","volume":"43","author":"A Abi\u010di\u0107","year":"2022","unstructured":"Abi\u010di\u0107 A, Adamec I, Habek M. Miller Fisher syndrome following Pfizer COVID-19 vaccine. Neurol Sci. 2022;43:1495\u20137. https:\/\/doi.org\/10.1007\/s10072-021-05776-0.","journal-title":"Neurol Sci"},{"key":"2838_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2147\/NDT.S343438","volume":"18","author":"SA Assiri","year":"2022","unstructured":"Assiri SA, Althaqafi RMM, Alswat K, Alghamdi AA, Alomairi NE, Nemenqani DM, et al. Post COVID-19 vaccination-associated neurological complications. Neuropsychiatr Dis Treat. 2022;18:137\u201354. https:\/\/doi.org\/10.2147\/NDT.S343438.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2838_CR19","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1002\/jmv.26996","volume":"93","author":"RAK Kadali","year":"2021","unstructured":"Kadali RAK, Janagama R, Peruru S, Gajula V, Madathala RR, Chennaiahgari N, et al. Non-life-threatening adverse effects with COVID-19 mrna-1273 vaccine: a randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms. J Med Virol. 2021;93:4420\u20139.","journal-title":"J Med Virol"},{"key":"2838_CR20","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40261-020-00952-0","volume":"40","author":"A Kamath","year":"2020","unstructured":"Kamath A, Maity N, Nayak MA. Facial paralysis following influenza vaccination: a disproportionality analysis using the vaccine adverse event reporting system database. Clin Drug Investig. 2020;40:883\u20139. https:\/\/doi.org\/10.1007\/s40261-020-00952-0.","journal-title":"Clin Drug Investig"},{"key":"2838_CR21","doi-asserted-by":"publisher","first-page":"e15935","DOI":"10.7759\/cureus.15935","volume":"13","author":"H Iftikhar","year":"2021","unstructured":"Iftikhar H, Noor SMU, Masood M, Bashir K. Bell\u2019s palsy after 24 hours of mrna-1273 SARS-Cov-2 vaccine. Cureus. 2021;13:e15935. https:\/\/doi.org\/10.7759\/cureus.15935.","journal-title":"Cureus."},{"key":"2838_CR22","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1001\/jamainternmed.2021.2219","volume":"181","author":"L Renoud","year":"2021","unstructured":"Renoud L, Khouri C, Revol B, Lepelley M, Perez J, Roustit M, et al. Association of facial paralysis with mRNA COVID-19 vaccines: a disproportionality analysis using the World Health Organization pharmacovigilance database. JAMA Intern Med. 2021;181:1243\u20135. https:\/\/doi.org\/10.1001\/jamainternmed.2021.2219.","journal-title":"JAMA Intern Med"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02838-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02838-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02838-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T13:06:18Z","timestamp":1661173578000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02838-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2838"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02838-4","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]},"assertion":[{"value":"28 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Human Research Ethics Committee\/Institutional Review Board of Kanto Central Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"309"}}